GILD Stock Analysis: Gilead Sciences | NASDAQ
Drug Manufacturers - General | NASDAQ, USA | Market Cap: 208.476m USD | 12M Return: 38.4% | US3755581036 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.02B
Qual. Beats: 2
Rev. Trend: 98.3%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Gilead Sciences is a U.S.-based biopharmaceutical company that discovers, develops, and commercializes medicines addressing unmet medical needs across the United States, Europe, and international markets. Its portfolio spans several therapeutic areas, including HIV (Biktarvy, Descovy, Sunlenca), viral hepatitis (Epclusa, Vemlidy), oncology cell therapies (Yescarta, Tecartus, Trodelvy), serious fungal infections (AmBisome), and COVID-19 (Veklury). The company also pursues immunotherapies for cancer and other intractable diseases.
Gilead operates a diversified pipeline supported by numerous external partnerships and licensing agreements with entities such as Arcus Biosciences, Merck, Janssen, Everest Medicines, and LEO Pharma, among others. The company was incorporated in 1987 and is headquartered in Foster City, California.
As a large-cap biotechnology firm, Gileads business model centers on high-risk, high-reward drug development, where revenue is generated primarily through the commercialization of patented therapeutics and supplemented by milestone payments and royalties from collaboration partners. The companys heavy reliance on a few blockbuster franchises, particularly in HIV, makes its financial performance sensitive to patent expirations, pipeline success, and regulatory approvals in its key markets.
- Lenacapavir PrEP approval drives HIV prevention revenue
- Trodelvy and Yescarta CAR-T sales growth offsets declines
- Hepatitis C franchise continues eroding as patient pool shrinks
| Net Income: -3.86b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.27 > 0.02 and ΔFCF/TA 11.15 > 1.0 |
| NWC/Revenue: 14.69% < 20% (prev 19.17%; Δ -4.48% < -1%) |
| CFO/TA 0.28 > 3% & CFO 14.5b > Net Income -3.86b |
| Net Debt (19.8b) to EBITDA (1.29b): 15.32 < 3 |
| Current Ratio: 1.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.25b) vs 12m ago -0.24% < -2% |
| Gross Margin: 79.93% > 18% (prev 78.71%; Δ 1.22% > 0.5%) |
| Asset Turnover: 56.37% > 50% (prev 49.69%; Δ 6.68% > 0%) |
| Interest Coverage Ratio: -1.51 > 6 (EBIT TTM -1.52b / Interest Expense TTM 1.01b) |
| A: 0.09 (Total Current Assets 16.6b - Total Current Liabilities 12.0b) / Total Assets 51.4b |
| B: 0.06 (Retained Earnings 3.11b / Total Assets 51.4b) |
| C: -0.03 (EBIT TTM -1.52b / Avg Total Assets 55.0b) |
| D: 0.34 (Book Value of Equity 13.0b / Total Liabilities 38.5b) |
| Altman-Z'' = 0.95 = BB |
| DSRI: 0.92 (Receivables 5.01b/5.09b, Revenue 31.0b/29.1b) |
| GMI: 0.98 (GM 78.71% / 79.93%) |
| AQI: 0.94 (AQ_t 0.56 / AQ_t-1 0.60) |
| SGI: 1.07 (Revenue 31.0b / 29.1b) |
| TATA: -0.36 (NI -3.86b - CFO 14.5b) / TA 51.4b) |
| Beneish M = -3.13 (Cap -4..+1) = AA |
As of November 17, 2026, the stock is trading at USD 167.58 with a total of 4,582,767 shares traded. Over the past week, the price has changed by -1.03%, over one month by +7.29%, over three months by +21.31% and over the past year by +38.38%.
Current recommended Stop Loss: 159.70 (which is 4.7% or 1.7 ATR below the current price).
Gilead Sciences has received a consensus analysts rating of 4.32. Therefore, it is recommended to buy GILD.
- StrongBuy: 16
- Buy: 6
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 174.8 | 4.3% |
P/E Forward = 16.8067
P/S = 6.7276
P/B = 15.9899
P/EG = 2.2702
Revenue TTM = 31.0b USD
EBIT TTM = -1.52b USD
EBITDA TTM = 1.29b USD
Long Term Debt = 23.8b USD (from longTermDebt, last quarter)
Short Term Debt = 2.42b USD (from shortTermDebt, last quarter)
Debt = 26.2b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 19.8b USD (calculated: Debt 26.2b - CCE 6.44b)
Enterprise Value = 228b USD (208b + Debt 26.2b - CCE 6.44b)
Interest Coverage Ratio = -1.51 (Ebit TTM -1.52b / Interest Expense TTM 1.01b)
EV/FCF = 16.57x (Enterprise Value 228b / FCF TTM 13.8b)
FCF Yield = 6.04% (FCF TTM 13.8b / Enterprise Value 228b)
FCF Margin = 44.47% (FCF TTM 13.8b / Revenue TTM 31.0b)
Net Margin = -12.47% (Net Income TTM -3.86b / Revenue TTM 31.0b)
Gross Margin = 79.93% ((Revenue TTM 31.0b - Cost of Revenue TTM 6.22b) / Revenue TTM)
Gross Margin QoQ = 81.07% (prev 79.76%)
Tobins Q-Ratio = 4.44 (Enterprise Value 228b / Total Assets 51.4b)
Interest Expense / Debt = 3.85% (Interest Expense 1.01b / Debt 26.2b)
Taxrate = 20.70% (634.0m / 3.06b)
NOPAT = -1.21b (EBIT -1.52b * (1 - 20.70%)) [loss with tax shield]
Current Ratio = 1.38 (Total Current Assets 16.6b / Total Current Liabilities 12.0b)
Debt / Equity = 2.01 (Debt 26.2b / totalStockholderEquity, last quarter 13.0b)
Debt / EBITDA = 15.32 (Net Debt 19.8b / EBITDA 1.29b)
Debt / FCF = 1.44 (Net Debt 19.8b / FCF TTM 13.8b)
Total Stockholder Equity = 17.8b (last 4 quarters mean from totalStockholderEquity)
RoA = -7.03% (Net Income -3.86b / Total Assets 51.4b)
RoE = -21.74% (Net Income TTM -3.86b / Total Stockholder Equity 17.8b)
RoCE = -3.66% (EBIT -1.52b / Capital Employed (Equity 17.8b + L.T.Debt 23.8b))
RoIC = -3.00% (negative operating profit) (NOPAT -1.21b / Invested Capital 40.3b)
WACC = 5.80% (E(208b)/V(235b) * Re(6.14%) + D(26.2b)/V(235b) * Rd(3.85%) * (1-Tc(0.21)))
Discount Rate = 6.14% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -48.83 | Cagr: 0.0%
[DCF] Terminal Value 77.97% ; FCFF base≈11.9b ; Y1≈13.7b ; Y5≈20.1b
[DCF] Fair Price = 228.3 (EV 303b - Net Debt 19.8b = Equity 283b / Shares 1.24b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.36 | # QB: 2
Revenue Correlation: 98.28 | Revenue CAGR: 4.45% | SUE: 2.18 | # QB: 2
EPS current Quarter (2027-03-31): EPS=2.14 | Chg30d=-7.28% | Revisions=-29% | Analysts=6
EPS current Year (2026-12-31): EPS=-0.98 | Chg30d=-143.56% | Revisions=-88% | GrowthEPS=-112.1% | GrowthRev=+6.5%
EPS next Year (2027-12-31): EPS=10.13 | Chg30d=+1.95% | Revisions=+59% | GrowthEPS=+1130.4% | GrowthRev=+7.0%
[Analyst] Revisions Ratio: -17% (up=21, down=30)